Novo Nordisk ® 3 across all therapy areas with within Obesity and OSCD The phase 3 CVOT with Ziltivekimab has been initiated ZEUS to include 6,200 patients Ziltivekimab 15 mg sc. once-monthly + SoC R 1:1 Placebo sc. once-monthly + SoC Treatment period (event driven) 13 weeks follow-up Objective • To investigate the cardiovascular benefit of ziltivekimab in the treatment of patients with established ASCVD, CKD and systemic inflammation Primary endpoints • Time to the first occurrence of 3-point MACE (CV death, non- fatal MI or non-fatal stroke) ion rate; HF: Heart failure; hsCRP: High-sensitivity C-reactive protein; MACE: Major adverse cardiovascular event; SoC: Standard of
Download PDF file